News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
Toggle Summary Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto , who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr.
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto , who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr.
Toggle Summary Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly. SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly. SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer
Toggle Summary Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 SAN DIEGO , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 SAN DIEGO , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment
Toggle Summary Adamis Announces Agreement to Sell Portion of US Compounding Business
Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline SAN DIEGO , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a
Adamis Announces Agreement to Sell Portion of US Compounding Business
Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline SAN DIEGO , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a
Toggle Summary Adamis Announces Results of 2021 Annual Meeting of Stockholders
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector
Adamis Announces Results of 2021 Annual Meeting of Stockholders
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector
Toggle Summary Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the
Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the
Toggle Summary Adamis Sends Letter to Stockholders to Address Jerald A. Hammann’s Costly, Distracting and Misguided Campaign
Asserts That Mr. Hammann — the Owner of Only 1,000 Shares — is Threatening the Company’s Strategic Progress Notes the Delaware Court of Chancery Denied Mr . Hammann’s Effort to Stop the Company From Sending Stockholders Proxy Materials and Holding its Annual Meeting as Scheduled Urges Stockholders
Adamis Sends Letter to Stockholders to Address Jerald A. Hammann’s Costly, Distracting and Misguided Campaign
Asserts That Mr. Hammann — the Owner of Only 1,000 Shares — is Threatening the Company’s Strategic Progress Notes the Delaware Court of Chancery Denied Mr . Hammann’s Effort to Stop the Company From Sending Stockholders Proxy Materials and Holding its Annual Meeting as Scheduled Urges Stockholders
Toggle Summary Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
Believes Maintaining Board Continuity is Critical to Continuing to Pursue Progress Related to Tempol Urges Stockholders to Elect the Company’s Highly-Qualified Directors at the July 16 th Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
Believes Maintaining Board Continuity is Critical to Continuing to Pursue Progress Related to Tempol Urges Stockholders to Elect the Company’s Highly-Qualified Directors at the July 16 th Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
Toggle Summary Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders
Highlights the Company’s High-Potential Products and Pipeline Notes the Current Board and Management Have Presided Over Significant Outperformance Over the Past Year Urges Stockholders to Sign, Date and Promptly Return the WHITE Proxy Card to Elect the Company’s Highly-Qualified Directors at the
Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders
Highlights the Company’s High-Potential Products and Pipeline Notes the Current Board and Management Have Presided Over Significant Outperformance Over the Past Year Urges Stockholders to Sign, Date and Promptly Return the WHITE Proxy Card to Elect the Company’s Highly-Qualified Directors at the
Toggle Summary Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 SAN DIEGO , June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 SAN DIEGO , June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of
Toggle Summary Adamis Provides Update on ZIMHI™
FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 SAN DIEGO , June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the
Adamis Provides Update on ZIMHI™
FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 SAN DIEGO , June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the
Toggle Summary Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the Treatment of COVID-19 SAN DIEGO , June 07, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the Treatment of COVID-19 SAN DIEGO , June 07, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
Toggle Summary Adamis Pharmaceuticals Provides Business Update
NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19 SAN DIEGO , June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for
Adamis Pharmaceuticals Provides Business Update
NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19 SAN DIEGO , June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for
Toggle Summary Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
SAN DIEGO , May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25, 2021 , it
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
SAN DIEGO , May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25, 2021 , it
Toggle Summary Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021 , at 2 p.m. Pacific Time .
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021 , at 2 p.m. Pacific Time .
Toggle Summary Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to
Toggle Summary Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Toggle Summary Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT SAN DIEGO , April 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT SAN DIEGO , April 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
Toggle Summary Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
SAN DIEGO , April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
SAN DIEGO , April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Toggle Summary Adamis Pharmaceuticals Provides an Update on ZIMHI™
SAN DIEGO , April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI ™ high-dose naloxone injection product intended for the treatment of opioid overdose.
Adamis Pharmaceuticals Provides an Update on ZIMHI™
SAN DIEGO , April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI ™ high-dose naloxone injection product intended for the treatment of opioid overdose.
Toggle Summary Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes
Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes
Toggle Summary Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) --   Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) --   Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that
Toggle Summary Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
SAN DIEGO , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI ™  high dose naloxone injection product candidate, intended for the treatment of
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
SAN DIEGO , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI ™  high dose naloxone injection product candidate, intended for the treatment of
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
SAN DIEGO , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
SAN DIEGO , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to